Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.35 USD
-0.02 (-5.00%)
Updated Aug 28, 2024 03:58 PM ET
After-Market: $0.34 -0.01 (-3.30%) 7:32 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Brokerage Reports
Aptevo Therapeutics Inc. [APVO]
Reports for Purchase
Showing records 41 - 60 ( 98 total )
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q21: APVO436 In Phase 1b, Cash Through 3Q22, PT to $36 from $50
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Publishes Positive Phase 1b APVO436 Data Showing Efficacy & RP2D Selected
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q21: APVO436 Phase 1 Complete, Funded Through 3Q22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Clean APVO436 Safety Supports Combo Rx, But We View Takeout as the Story
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Well-Funded Through 2022, APVO436 Progressing Through Dose Cohort 10
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Preclinical Updates for APVO603 and APVO442 at AACR
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q20: Well-Funded, Monetizes Ruxience Royalty, APVO436 in Dose Cohort 10
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Annual ROTH Conference: Cancer Panel Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Interim Phase 1/1b AML/MDS Details at ASH Show Efficacy & Safety
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J